Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results